



Universiteit
Leiden
The Netherlands

The challenge of quality assessment and regional perfusion to increase donor organ utilisation

Leemkolk, F.E.M. van de

Citation

Leemkolk, F. E. M. van de. (2024, May 15). *The challenge of quality assessment and regional perfusion to increase donor organ utilisation*. Retrieved from <https://hdl.handle.net/1887/3754038>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3754038>

Note: To cite this publication please use the final published version (if applicable).



Chapter 1

General introduction and outline of the thesis

Fenna E.M. van de Leemkolk

Organ Donation

Organ transplantation has been one of the most impressive achievements in modern clinical medicine. Due to its success, an increasing number of patients is waitlisted for transplantation whilst the gap between the demand and the number of available donor organs is widening.^{1,2} As a result of this donor shortage, many transplant centres are accepting organs from older and higher risk donors for transplantation, including those obtained from extended criteria donors (ECD) and donation after circulatory death (DCD) donors.

Extended Criteria Donors

Although organs that are considered to be extended criteria donor organs may seem a well-defined entity, in reality, the definition and criteria vary between the type of donor organ. As regards the kidney, ECDs are brain-dead donors and defined according to the UNOS (United Network for Organ Sharing) to include donors either over the age of 60 years, or older than 50 years but with at least two of the following donor medical risk factors: a history of hypertension, a cerebrovascular accident as the cause of death, a serum creatinine (SCr) >1.5 mg/dL (132 µmol/L) prior to organ retrieval.^{3,4} In donation after brain death (DBD) donors - including higher risk ECDs - following the diagnosis of brain death, donor management will continue and support haemodynamic and metabolic stability. The perfusion of all donor organs remains optimised until the circulation stops and the organs are retrieved. As a consequence, in DBD donors, in the presence of perfusion and absence of hypoxia, warm ischaemic time of donor organs does not occur.

ECDs are widely used in kidney transplantation. Transplantation of kidneys from these donors is often associated with delayed graft function (DGF) posttransplant and a decrease in graft survival when compared with grafts from standard criteria donors.⁵⁻⁸ In liver transplantation several risk models have been introduced, predominantly based on donor and recipient factors, to predict the outcome after transplantation.⁹ To identify a liver graft as higher risk or ECD, a variety of donor factors including demographic characteristics, aspects of donor management, liver function tests, and the presence of steatosis are used.¹⁰⁻¹³ Transplantation of these higher risk liver grafts is associated with early allograft dysfunction (EAD), primary non (and never) function (PNF), and an increased complication rate.^{11,14-18}

Donation after circulatory death donors

Prior to the brain death laws in the mid 70s all organ transplants using deceased donors were obtained from the so-called non-heart-beating donors (NHBD).¹⁹ NHBD was renamed as donation after cardiac death and then modified to donation after

circulatory death (DCD) as the circulation has stopped but the heart is not 'dead'.²⁰ DCD donation was classified for the first time during an international workshop in Maastricht in the Netherlands in 1995 by Kootstra et al.²¹ establishing the four categories of the 'Non Heart Beating Donor (NHBD) Maastricht Classification'. On several occasions modifications of this classification of DCD donors have been described.²² During the 6th International DCD Conference in Paris in 2013, consensus about definitions and terminology was reached as regards DCD and published.²³ **Table 1** illustrates the main five categories. In the Netherlands, all types of DCD donors are permitted, although there is currently no active protocol for types I, II and IV DCD donation.

DCD donors are an important resource to effectively increase the numbers of donor organs. Ideally, this donor type will add extra organs for transplantation to the pool of donor organs. In 2010, in the Netherlands, 32% of deceased donors were DCD donors and this increased to 60% in 2020.^{2,24} In the United Kingdom, the number of DCD donors increased over the last decade from 336 donors in 2009-2010 to 634 in 2019-2020, representing 40% of all deceased donors.^{25,26}

In DCD donation a patient's neurological condition and prognosis is considered to be irreversible and further medical treatment futile. Therefore, following consent from the family or legal guardian, life sustaining therapy is withdrawn, and the patient is extubated. This will result in a respiratory arrest followed by a circulatory arrest and the death of the patient. The time from extubation, initiating a period of hypoxia in the donor organs, to circulatory arrest can vary per patient. Therefore, times of warm ischaemia may vary between DCD donors. Furthermore, the duration of the no-touch period, defined as the time between circulatory arrest and the determination of (neurological) death, varies widely across countries (ranging from 5 to 30 minutes) contributing to the warm ischaemia time.²⁷ Despite that consent has been given for organ donation, in most countries any activities towards the retrieval and preservation of the donor organs (e.g., pre-mortem administration of substances or cannulation) are prohibited and only legally permitted after the declaration of death.²⁷

In DCD donation the period of donor total warm ischaemia time, defined as the time between withdrawal of life sustaining support and the start of cold perfusion during retrieval, is inevitable. During this warm ischaemia time, hypoxia and hypotension followed by the circulatory arrest in the donor will result in ischaemic injury of the organs. However, the exact amount of additional damage to the organs is unknown and this makes the donor a 'black box' since the extent of the injury will only become apparent after transplantation in the recipient. Results after transplantation of higher risk DCD donor organs using strict selection criteria are acceptable but remain

associated with poorer initial graft function^{17,18,28,29} and organ specific complications when compared to standard criteria donors.³⁰⁻³² Due to the concerns regarding the quality of the DCD donor organs, the decision whether to accept or decline a donor organ at time of offering is more difficult for the clinician and probably many DCD donor organs are discarded as they are perceived as “not transplantable”. Registry data reveal that DCD procedures are associated with significantly lower organ recovery rates per donor than in DBD donors.^{27,33,34} To reduce uncertainty and increase utilisation, improved assessment of organ viability and optimisation of preservation strategies are required.

Table 1. Modified Maastricht Classification for DCD donors.²³

<i>Category I</i>		
Uncontrolled	IA. Out-of-hospital IB. In-hospital	Found dead due to a sudden unexpected circulatory arrest without any attempt of resuscitation in the out-of-hospital or in-hospital setting
<i>Category II</i>		
Uncontrolled	IIA. Out-of-hospital IB. In-hospital	Witnessed circulatory arrest with unsuccessful resuscitation, including the addition of the location
<i>Category III</i>		
Controlled	III	Ventilated patients awaiting circulatory arrest where the withdrawal of life sustaining therapy is planned
<i>Category IV</i>		
Uncontrolled Controlled	IV	Sudden (or unexpected) circulatory arrest after declaration of brain death (uDCD IV) or when the law does not permit the declaration of brain death (e.g., Japan or China) a donation after brain death donor is followed by controlled circulatory arrest (cDCD IV)
<i>Category V</i>		
Controlled	V	Euthanasia or medically assisted cardiocirculatory death

Donor Organ Assessment

To date, the decision to accept or decline a donor organ is based on organ function prior to admission and during donor management as well as considering known risk factors in donor and/or recipient and the macroscopic appearance of the graft. Clinical expertise and the more subjective perception of risk also play an important role. A more cautious attitude of clinicians towards accepting higher risk organs may reduce the incidence of poor graft survival in recipients on one hand, however, on the other hand it will further compromise the donor pool and as such contribute to donor organ shortage. As clinical decisions about suitability and perceived risk of donor organs carry a high degree of subjectivity, there is a need for evidence and clinically relevant markers to help the decision to accept the organ at time of offering.

The National Institutes of Health Biomarkers Definitions Working Group has defined a biomarker as follows: “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention”. During the different phases of transplantation, from donor management to donor organ retrieval and eventually transplantation in the recipient, an ideal biomarker should function as a useful tool to rapidly, accurately, and objectively assess the viability and quality of the organ.

Over the past years, multi-analyte ‘omics’ technologies including proteomics and metabolomics have been increasingly used to identify novel biomarkers in transplantation, and this field of research is constantly evolving.³⁵⁻⁴¹ In proteomics research, the complete set of proteins (proteome) in a biological sample is analysed. Individual proteins are separated from complex mixtures, quantified, characterised, and finally identified. Metabolomic research involves the high-throughput measurement and dynamic analysis of low molecular mass cellular products (i.e., metabolites) in the metabolome. Proteomics and metabolomics allow for the identification of molecular signatures and can be used to generate a diagnostic fingerprint. As such, prognostic biomarkers are of interest as they may predict posttransplant outcomes. These biomarkers can be analysed during management in the donor but also when a graft is perfused after retrieval on a dedicated device prior to transplantation (see Machine Preservation of Abdominal Organs below). In both situations, it allows for assessment of the organ and to quantify the amount of sustained injury present in the organ.

Another exciting and emerging field of research is based on DNA methylation. The epigenetic process of the methylation of cytosine adjacent to guanine (CpG sites) results in cell type specific gene regulation and as such functions as a fundamental mark of cell identity.⁴² As DNA methylation patterns can be used to identify cell death in specific tissues, it may be considered as an highly interesting method to unravel mechanisms of injury and repair in organ donation and transplantation.⁴³⁻⁴⁵

Machine Preservation of Abdominal Organs

In the past 50 years the predominant method of organ preservation when bridging from the donor hospital to the recipient transplant centre has been a simple form of Static Cold Storage (SCS).⁴⁶ To maintain viability, donor organs are flushed after retrieval with a cold preservation solution, subsequently submerged in the same preservation solution in a plastic bag and stored on melting ice in a box. Hypothermia has been one of the basic principles in organ preservation. Aiming at a core temperature of the donor organ of 2-5°C, the cellular metabolism is decreased and this in turn slows

down the deterioration of the organ significantly. SCS is a simple way to preserve, store, and transport transplantable organs and it sufficed for many years whilst the average donor was young and without too much co-morbidity prior to admission.

Whilst ECD and DCD organs are accepted due to a shortage of better quality organs, the transplant community realises that optimising organ preservation strategies has become an absolute necessity aiming to better protect vulnerable grafts and enhance organ quality and function.^{47,48}

The historic concept of dynamic organ preservation, was first developed in the 1930's by Carrel and Lindbergh.^{49,50} The group of Belzer and Starzl further established hypothermic dynamic preservation in clinical kidney transplantation in the late 1960's.^{46,51} During the past decade and in the context of developments in miniaturised pump technologies, novel portable and more user friendly devices were developed. Dynamic preservation techniques are increasingly used in clinical practice⁵²⁻⁵⁴ and described in more detail below. **Figure 1** demonstrates the different organ preservation strategies used in clinical practice from donor to recipient.




Figure 1. An overview of the several possibilities in organ preservation from donor to recipient currently used in clinical practice. In-Situ Machine Perfusion is performed in the donor on hypo- or normothermic conditions. Ex-situ Machine Perfusion might be performed at hypothermic (0-4°C), subnormothermic (20-25°C) or normothermic (37°C) temperatures.

When machine perfusion is used, in most techniques after retrieval, the donor organ is connected to a pump device (ex-situ; outside of the donor or recipient) and perfused with preservation solution. Machine perfusion can be applied in a continuous fashion

(from retrieval in the donor hospital until implantation in the recipient centre) or just for a fixed period of time (e.g., following SCS and for a few hours immediately prior to implantation in the recipient, as an end-ischaemic hypo- or normothermic perfusion).

Hypothermic (oxygenated) Machine Perfusion (HMP/HMPO₂)

During HMP, continuous circulation with acellular preservation solution is used at a temperature ranging between 5–10°C. Superior function and better survival in kidney transplantation using HMP compared with SCS has been reported.^{55–58} Due to the hypothermic condition, the cellular metabolic activity is decreased but not completely ceased. As such, the addition of oxygen in HMP (HMPO₂) to restore ATP content and reduce oxidative stress may support the organ during the aerobic activity.^{59–61} The beneficial effect of the addition of oxygen in HMPO₂ leads to improvement of graft function when compared with standard HMP.⁶² As regards the liver, HMP was found to be feasible in animal models and first tested by Guarrera et al.⁶³ in a clinical pilot case-controlled series in 2010. More recently, a multicentre randomised controlled trial showed that hypothermic oxygenated machine perfusion of DCD livers led to a lower risk of non-anastomotic biliary strictures (NAS) when compared to SCS.⁶⁴ Successful preservation of the human pancreas using HMP was described as feasible and safe and a clinically relevant number of viable islets could be isolated after 6 hrs of HMPO₂.^{65–67}

Normothermic Machine Perfusion (NMP)

In NMP, the organ is either continuously or during a fixed period perfused with oxygenated blood at 37°C. Nutrients and metabolic compounds are administered during NMP to aim for a more physiological state. During NMP, normal cellular activity is resumed which allows the organ to recover after a period of cold flush and cold storage or HMP. Normal temperature allows for better assessment and testing the viability of the organ. Another advantage of NMP is the possibility to provide targeted interventions aiming to optimise the quality of the injured organ. Using pharmacological and biological agents, or mesenchymal stem cells, repair or even regeneration in the donor organ is stimulated. Continuous NMP of the liver and NMP of the kidney have been found to be safe and feasible.^{68,69} As regards the pancreas, NMP is not yet ready for clinical application and needs more refinement.⁷⁰

Normothermic Regional perfusion (NRP)

The technique of in-situ organ perfusion during donor surgery is known as regional perfusion (RP).⁷¹ In normothermic regional perfusion (NRP), cannulas are introduced via the iliac artery or distal aorta and connected to an extracorporeal membrane oxygenator (ECMO) to ensure the continuous perfusion of multiple organs simultaneously in the donor (in-situ) (**Figure 2**).




Figure 2. The technique of abdominal Normothermic Regional Perfusion (aNRP)

NRP was first pioneered in Spain in 1989. Preliminary experiments in a porcine DCD model showed that warm perfusion, using the aorta in the donor animal, was feasible and improved liver graft viability.^{72,73} It was introduced in clinical practice in Belgium, China, France, Italy, the Netherlands, Norway, Portugal, Russia, Spain, Switzerland, the United Kingdom and the United States of America.

During hypothermic regional perfusion, also called ‘core-cooling technique’, the donor is actively cooled, and a continuous gas exchange can take place during the organ recovery rate. The oxygen consumption decreases as normal metabolic processes are reduced due to the efficient cooling.⁷⁴⁻⁷⁶ Despite the theoretical benefits for its use, the literature for this technique in clinical setting is scarce and therefore not described in further detail here.^{77,78}

NRP can be applied for abdominal organs (i.e., liver, pancreas, and kidneys) only (aNRP), but also in combination with heart and lungs in the thoracic compartment (TA-NRP). During NRP, a normothermic oxygenated circulation is restored in the donor resulting in recommencing cellular metabolism. This allows for actual assessment of the donor organ viability as biochemical analysis of blood samples can be obtained in a non-invasive way from the circuit. As such, the ‘black box’ of DCD becomes more transparent, helping the clinician to decide whether to accept or decline the abdominal organs for transplantation. Initiation of NRP as soon as possible after circulatory arrest will reduce the extent of ischaemic injury, incurred during the dying process of the DCD donor. It will also affect in a positive way the inevitable vasoconstriction.⁷⁹ Using NRP will allow to convert a ‘hasty’ surgical DCD procedure, where time is of essence, into a less rushed and more stable ‘DBD-like’ operation potentially resulting in less organ damage and increasing organ utilisation.⁸⁰⁻⁸² In addition, aNRP of liver, pancreas and kidneys in DCD donors may be more cost-effective when compared to the application of ex-situ HMP or NMP for each individual organ. However, a cost-effectiveness analysis of this technique remains to be investigated.

Thesis Outline and Rationale

The ongoing shortage of donor organs has led to acceptance by most transplant centres of older and higher risk organs to increase the donor pool in solid organ transplantation. In the General Introduction in **Chapter 1** the necessity is described to improve assessment of donor organs by identifying clinically relevant markers and establish a method of machine preservation in higher risk donors that will promote a more rapid resuscitation of organ function and better organ quality in transplantation.

In the **first part of this thesis**, we evaluate the results achieved with the current use of older and higher risk donor kidneys. **Chapter 2** focuses on the transplantation of kidneys from donors with Acute Kidney Injury (AKI) which is perceived by many transplant professionals as a relative contraindication for transplantation. As the kidney has an intrinsic capacity to recover from this abrupt deterioration of kidney function, we hypothesise that using kidneys from donors with an AKI could reduce an unnecessary discard and expand the donor pool whilst not impacting on clinical outcomes. To determine whether discarding AKI donor kidneys is justified, we investigate the effect of donor AKI on outcomes following kidney transplantation analysing large cohorts of donor-recipient combinations from the National Transplant Database in the United Kingdom hosted by NHS Blood and Transplant.

Objective criteria are lacking how to assess donor organ quality. The goal of the studies in the following chapters describes the attempt to identify clinically relevant biomarkers as well as develop an assay that can give clinicians sufficient guidance during the decision whether to accept or decline an organ for transplantation.

In **Chapter 3** we analyse blood and urine from donation after circulatory death (DCD) donors before retrieval. The donor kidneys retrieved from these donors developed either immediate function (IF), delayed graft function (DGF) or primary non-function (PNF) after transplantation. The goal in this chapter is to determine whether a molecular signature can be identified in the donor associated with each of these different clinically early outcomes using a proteomic approach.

Following the publication that Flavin Mononucleotide (FMN) release into the perfusate, during Hypothermic Machine Perfusion (HMP) of livers, predicts success or failure after liver transplantation, we engaged in a study to validate this role of FMN in kidney perfusion. In **Chapter 4** we report our analysis and results as regards the use of this marker in kidney transplantation using a large cohort of samples obtained during Hypothermic (oxygenated) Machine Perfusion (HMPO₂ or HMP). Fluorescence spectroscopy is used to assess fluorescence intensity in the FMN region and subsequently correlated with early and late post transplantation outcomes for the kidney. Targeted liquid chromatography mass spectrometry is applied to validate the results.

In **Chapter 5** we aim to develop a novel method to quantify the relative amount of unmethylated Insulin (*INS*)-DNA, reflecting β -cell death. Using a methylation sensitive restriction enzyme digital droplet PCR, the goal is to validate this assay on two cell lines and further extend the use of this assay by measuring the fraction of unmethylated Insulin (*INS*)-DNA, reflecting β -cell death, in different purities of islets obtained after pancreas isolation.

In the **second part of this thesis**, we focus on organ preservation strategies for abdominal organs to assess the quality of the graft.

Therefore, in **Chapters 6** and **7** we evaluate the novel organ preservation technique of abdominal normothermic regional perfusion (aNRP) that has been used in a few other countries in the past years and is now being introduced in clinical practice in the Netherlands. This method was developed to improve immediate function and outcomes from organs obtained from donation after circulatory death (DCD) donors. aNRP promises to allow a rapid resuscitation after circulatory arrest of the donor and better reconditioning prior transplantation when compared to standard preservation techniques of DCD donor organs. In **Chapter 6** we report the results of a systematic review of aNRP in DCD donors. We explore the literature focussing on the added value of aNRP when compared to standard organ perfusion techniques. In **Chapter 7** we investigate the current donor organ assessment used for the donor liver during aNRP.

Finally, in **Chapter 8**, we summarise the results of the studies in this thesis and provide a brief outlook and future perspectives.

References

1. Eurotransplant. *Annual Report 2021* Accessed June 14, 2022 https://www.eurotransplant.org/wp-content/uploads/2022/06/ET_Annual-Report-2021_LR.pdf.
2. Global Observatory on Donation and Transplantation. *International Report on Organ Donation and Transplantation Activities. Executive Summary 2020*. Accessed June 14, 2022 <http://www.transplant-observatory.org/2020-international-activities-report/>.
3. Metzger RA, Delmonico FL, Feng S, Port FK, Wynn JJ, Merion RM. Expanded criteria donors for kidney transplantation. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2003;3 Suppl 4:114-25.
4. Port FK, Bragg-Gresham JL, Metzger RA, Dykstra DM, Gillespie BW, Young EW, et al. Donor characteristics associated with reduced graft survival: an approach to expanding the pool of kidney donors. *Transplantation*. 2002;74(9):1281-6.
5. Han F, Lin MZ, Zhou HL, Li H, Sun QP, Huang ZY, et al. Delayed graft function is correlated with graft loss in recipients of expanded-criteria rather than standard-criteria donor kidneys: a retrospective, multicenter, observation cohort study. *Chin Med J (Engl)*. 2020;133(5):561-70.
6. Watson CJ, Johnson RJ, Birch R, Collett D, Bradley JA. A simplified donor risk index for predicting outcome after deceased donor kidney transplantation. *Transplantation*. 2012;93(3):314-8.
7. Hamed MO, Chen Y, Pasa L, Watson CJ, Torpey N, Bradley JA, et al. Early Graft Loss After Kidney Transplantation: Risk Factors and Consequences. *American Journal of Transplantation*. 2015;15(6):1632-43.
8. van Heurn LW, Talbot D, Nicholson ML, Akhtar MZ, Sanchez-Fructuoso AI, Weekers L, et al. Recommendations for donation after circulatory death kidney transplantation in Europe. *Transplant international : official journal of the European Society for Organ Transplantation*. 2016;29(7):780-9.
9. de Boer JD, Putter H, Blok JJ, Alwayn IPJ, van Hoek B, Braat AE. Predictive Capacity of Risk Models in Liver Transplantation. *Transplant Direct*. 2019;5(6):e457.
10. Durand F, Renz JF, Alkofer B, Burra P, Clavien PA, Porte RJ, et al. Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. *Liver Transpl*. 2008;14(12):1694-707.
11. Lozanovski VJ, Khajeh E, Fonouni H, Pfeiffenberger J, von Haken R, Brenner T, et al. The impact of major extended donor criteria on graft failure and patient mortality after liver transplantation. *Langenbeck's archives of surgery*. 2018;403(6):719-31.
12. Nemes B, Gaman G, Polak WG, Gelley F, Hara T, Ono S, et al. Extended criteria donors in liver transplantation Part I: reviewing the impact of determining factors. *Expert Rev Gastroenterol Hepatol*. 2016;10(7):827-39.
13. Jiménez-Romero C, Caso Maestro O, Cambra Molero F, Justo Alonso I, Alegre Torrado C, Manrique Municio A, et al. Using old liver grafts for liver transplantation: where are the limits? *World J Gastroenterol*. 2014;20(31):10691-702.
14. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2006;6(4):783-90.
15. Leithead JA, Taricciotti L, Gunson B, Holt A, Isaac J, Mirza DF, et al. Donation after cardiac death liver transplant recipients have an increased frequency of acute kidney injury. *American journal*

- of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2012;12(4):965-75.
16. Ploeg RJ, D'Alessandro AM, Knechtle SJ, Stegall MD, Pirsch JD, Hoffmann RM, et al. Risk factors for primary dysfunction after liver transplantation--a multivariate analysis. *Transplantation*. 1993;55(4):807-13.
 17. Blok JJ, Detry O, Putter H, Rogiers X, Porte RJ, van Hoek B, et al. Longterm results of liver transplantation from donation after circulatory death. *Liver Transpl*. 2016;22(8):1107-14.
 18. Callaghan CJ, Charman SC, Muiesan P, Powell JJ, Gimson AE, van der Meulen JH. Outcomes of transplantation of livers from donation after circulatory death donors in the UK: a cohort study. *BMJ Open*. 2013;3(9):e003287.
 19. Beecher HK. Harvard Ad Hoc Committee. A definition of irreversible coma. Report of the Ad Hoc Committee of the Harvard Medical School to Examine the Definition of Brain Death. *Jama*. 1968;205(6):337-40.
 20. Institute of Medicine (U.S.). *Organ Donation: Opportunities for Action*. Washington, DC: The National Academies Press.; 2006.
 21. Kootstra G, Daemen JH, Oomen AP. Categories of non-heart-beating donors. *Transplant Proc*. 1995;27(5):2893-4.
 22. Detry O, Le Dinh H, Noterdaeme T, De Roover A, Honoré P, Squifflet JP, et al. Categories of donation after cardiocirculatory death. *Transplant Proc*. 2012;44(5):1189-95.
 23. Thuong M, Ruiz A, Evrard P, Kuiper M, Boffa C, Akhtar MZ, et al. New classification of donation after circulatory death donors definitions and terminology. *Transplant international : official journal of the European Society for Organ Transplantation*. 2016;29(7):749-59.
 24. Eurotransplant. *Annual Report 2020* Accessed June 14, 2022 https://www.eurotransplant.org/wp-content/uploads/2022/03/ET_AR2020_LR_def.pdf.
 25. NHSBT. *Annual Report 2019-2020* Accessed June 14, 2022 <https://nhsbt.dbe.blob.core.windows.net/umbraco-assets-corp/19481/activity-report-2019-2020.pdf>.
 26. NHSBT. *Annual Report 2009-2010* Accessed June 14, 2022 https://nhsbt.dbe.blob.core.windows.net/umbraco-assets-corp/1282/activity_report_2009_10.pdf.
 27. Lomero M, Gardiner D, Coll E, Haase-Kromwijk B, Procaccio F, Immer F, et al. Donation after circulatory death today: an updated overview of the European landscape. *Transplant international : official journal of the European Society for Organ Transplantation*. 2020;33(1):76-88.
 28. Schaapherder A, Wijermars LGM, de Vries DK, de Vries APJ, Bemelman FJ, van de Wetering J, et al. Equivalent Long-term Transplantation Outcomes for Kidneys Donated After Brain Death and Cardiac Death: Conclusions From a Nationwide Evaluation. *EClinicalMedicine*. 2018.
 29. Summers DM, Watson CJ, Pettigrew GJ, Johnson RJ, Collett D, Neuberger JM, et al. Kidney donation after circulatory death (DCD): state of the art. *Kidney Int*. 2015;88(2):241-9.
 30. O'Neill S, Roebuck A, Khoo E, Wigmore SJ, Harrison EM. A meta-analysis and meta-regression of outcomes including biliary complications in donation after cardiac death liver transplantation. *Transplant international : official journal of the European Society for Organ Transplantation*. 2014;27(11):1159-74.
 31. Jay CL, Lyuksemburg V, Ladner DP, Wang E, Caicedo JC, Holl JL, et al. Ischemic Cholangiopathy After Controlled Donation After Cardiac Death Liver Transplantation. *Annals of surgery*. 2011;253(2):259-64.
 32. Shahrestani S, Webster AC, Lam VW, Yuen L, Ryan B, Pleass HC, et al. Outcomes From Pancreatic Transplantation in Donation After Cardiac Death: A Systematic Review and Meta-Analysis. *Transplantation*. 2017;101(1):122-30.

33. Dominguez-Gil B, Haase-Kromwijk B, Van Leiden H, Neuberger J, Coene L, Morel P, et al. Current situation of donation after circulatory death in European countries. *Transplant international : official journal of the European Society for Organ Transplantation*. 2011;24(7):676-86.
34. Bendorf A, Kelly PJ, Kerridge IH, McCaughan GW, Myerson B, Stewart C, et al. An international comparison of the effect of policy shifts to organ donation following cardiocirculatory death (DCD) on donation rates after brain death (DBD) and transplantation rates. *PloS one*. 2013;8(5):e62010.
35. Bruinsma BG, Sridharan GV, Weeder PD, Avruch JH, Saeidi N, Ozer S, et al. Metabolic profiling during ex vivo machine perfusion of the human liver. *Scientific reports*. 2016;6:22415.
36. Chen L, Su W, Chen H, Chen DQ, Wang M, Guo Y, et al. Proteomics for Biomarker Identification and Clinical Application in Kidney Disease. *Adv Clin Chem*. 2018;85:91-113.
37. Moser MAJ, Sawicka K, Arcand S, O'Brien P, Luke P, Beck G, et al. Proteomic Analysis of Perfusate from Machine Cold Perfusion of Transplant Kidneys: Insights Into Protection from Injury. *Ann Transplant*. 2017;22:730-9.
38. Sigdel TK, Kaushal A, Gritsenko M, Norbeck AD, Qian WJ, Xiao W, et al. Shotgun proteomics identifies proteins specific for acute renal transplant rejection. *Proteomics Clin Appl*. 2010;4(1):32-47.
39. Attard JA, Dunn WB, Mergental H, Mirza DF, Afford SC, Perera MTPR. Systematic Review: Clinical Metabolomics to Forecast Outcomes in Liver Transplantation Surgery. *OMICS: A Journal of Integrative Biology*. 2019;23(10):463-76.
40. Lo DJ, Kaplan B, Kirk AD. Biomarkers for kidney transplant rejection. *Nat Rev Nephrol*. 2014;10(4):215-25.
41. Guzzi F, Knight SR, Ploeg RJ, Hunter JP. A systematic review to identify whether perfusate biomarkers produced during hypothermic machine perfusion can predict graft outcomes in kidney transplantation. *Transplant international : official journal of the European Society for Organ Transplantation*. 2020;33(6):590-602.
42. Dor Y, Cedar H. Principles of DNA methylation and their implications for biology and medicine. *The Lancet*. 2018;392(10149):777-86.
43. Gala-Lopez BL, Neiman D, Kin T, O'Gorman D, Pepper AR, Malcolm AJ, et al. Beta Cell Death by Cell-free DNA and Outcome After Clinical Islet Transplantation. *Transplantation*. 2018;102(6):978-85.
44. Lehmann-Werman R, Neiman D, Zemmour H, Moss J, Magenheim J, Vaknin-Dembinsky A, et al. Identification of tissue-specific cell death using methylation patterns of circulating DNA. *Proceedings of the National Academy of Sciences of the United States of America*. 2016;113(13):E1826-34.
45. Moss J, Magenheim J, Neiman D, Zemmour H, Loyfer N, Korach A, et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. *Nat Commun*. 2018;9(1):5068.
46. Collins GM, Bravo-Shugarman M, Terasaki PI. Kidney preservation for transportation. Initial perfusion and 30 hours' ice storage. *Lancet*. 1969;2(7632):1219-22.
47. Peng P, Ding Z, He Y, Zhang J, Wang X, Yang Z. Hypothermic Machine Perfusion Versus Static Cold Storage in Deceased Donor Kidney Transplantation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Artif Organs*. 2019;43(5):478-89.
48. Brat A, Pol RA, Leuvenink HG. Novel preservation methods to increase the quality of older kidneys. *Curr Opin Organ Transplant*. 2015;20(4):438-43.
49. Lindbergh CA. An apparatus for the culture of whole organs. *J Exp Med*. 1935;62(3):409-31.

50. Carrel A. Landmark article, Nov 14, 1908: Results of the transplantation of blood vessels, organs and limbs. By Alexis Carrel. *Jama*. 1983;250(7):944-53.
51. Belzer FO, Ashby BS, Dunphy JE. 24-hour and 72-hour preservation of canine kidneys. *Lancet*. 1967;2(7515):536-8.
52. Jochmans I, Akhtar MZ, Nasralla D, Kocabayoglu P, Boffa C, Kaiser M, et al. Past, Present, and Future of Dynamic Kidney and Liver Preservation and Resuscitation. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2016;16(9):2545-55.
53. Rijkse E, JN IJ, Minnee RC. Machine perfusion in abdominal organ transplantation: Current use in the Netherlands. *World J Transplant*. 2020;10(1):15-28.
54. Lomero M, Gardiner D, Coll E, Haase-Kromwijk B, Procaccio F, Immer F, et al. Donation after circulatory death today: an updated overview of the European landscape. *Transpl Int*. 2019.
55. Jochmans I, Moers C, Smits JM, Leuvenink HG, Treckmann J, Paul A, et al. Machine perfusion versus cold storage for the preservation of kidneys donated after cardiac death: a multicenter, randomized, controlled trial. *Annals of surgery*. 2010;252(5):756-64.
56. Moers C, Smits JM, Maathuis MH, Treckmann J, van Gelder F, Napieralski BP, et al. Machine perfusion or cold storage in deceased-donor kidney transplantation. *N Engl J Med*. 2009;360(1):7-19.
57. Kox J, Moers C, Monbaliu D, Strelniec A, Treckmann J, Jochmans I, et al. The Benefits of Hypothermic Machine Preservation and Short Cold Ischemia Times in Deceased Donor Kidneys. *Transplantation*. 2018;102(8):1344-50.
58. Gallinat A, Moers C, Smits JM, Strelniec A, Pirenne J, Ploeg RJ, et al. Machine perfusion versus static cold storage in expanded criteria donor kidney transplantation: 3-year follow-up data. *Transplant international : official journal of the European Society for Organ Transplantation*. 2013;26(6):E52-3.
59. Schlegel A, Dutkowski P. Role of hypothermic machine perfusion in liver transplantation. *Transplant international : official journal of the European Society for Organ Transplantation*. 2015;28(6):677-89.
60. Buchs JB, Lazeyras F, Ruttimann R, Nastasi A, Morel P. Oxygenated hypothermic pulsatile perfusion versus cold static storage for kidneys from non heart-beating donors tested by in-line ATP resynthesis to establish a strategy of preservation. *Perfusion*. 2011;26(2):159-65.
61. Thuillier R, Allain G, Celhay O, Hebrard W, Barrou B, Badet L, et al. Benefits of active oxygenation during hypothermic machine perfusion of kidneys in a preclinical model of deceased after cardiac death donors. *J Surg Res*. 2013;184(2):1174-81.
62. Jochmans I, Brat A, Davies L, Hofker HS, van de Leemkolk FEM, Leuvenink HGD, et al. Oxygenated versus standard cold perfusion preservation in kidney transplantation (COMPARE): a randomised, double-blind, paired, phase 3 trial. *The Lancet*. 2020;396(10263):1653-62.
63. Guarrera JV, Henry SD, Samstein B, Odeh-Ramadan R, Kinkhabwala M, Goldstein MJ, et al. Hypothermic machine preservation in human liver transplantation: the first clinical series. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2010;10(2):372-81.
64. van Rijn R, Schurink IJ, de Vries Y, van den Berg AP, Cortes Cerisuelo M, Darwish Murad S, et al. Hypothermic Machine Perfusion in Liver Transplantation - A Randomized Trial. *N Engl J Med*. 2021;384(15):1391-401.
65. Leemkuil M, Lier G, Engelse MA, Ploeg RJ, de Koning EJP, t Hart NA, et al. Hypothermic Oxygenated Machine Perfusion of the Human Donor Pancreas. *Transplant Direct*. 2018;4(10):e388.

66. Doppenberg JB, Leemkuil M, Engelse MA, Krikke C, de Koning EJP, Leuvenink HGD. Hypothermic oxygenated machine perfusion of the human pancreas for clinical islet isolation: a prospective feasibility study. *Transplant international : official journal of the European Society for Organ Transplantation*. 2021;34(8):1397-407.
67. Branchereau J, Renaudin K, Kervella D, Bernadet S, Karam G, Blancho G, et al. Hypothermic pulsatile perfusion of human pancreas: Preliminary technical feasibility study based on histology. *Cryobiology*. 2018;85:56-62.
68. Nasralla D, Coussios CC, Mergental H, Akhtar MZ, Butler AJ, Ceresa CDL, et al. A randomized trial of normothermic preservation in liver transplantation. *Nature*. 2018;557(7703):50-6.
69. Nicholson ML, Hosgood SA. Renal transplantation after ex vivo normothermic perfusion: the first clinical study. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2013;13(5):1246-52.
70. Barlow AD, Hamed MO, Mallon DH, Brais RJ, Gribble FM, Scott MA, et al. Use of Ex Vivo Normothermic Perfusion for Quality Assessment of Discarded Human Donor Pancreases. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2015;15(9):2475-82.
71. Hessheimer AJ, Billault C, Barrou B, Fondevila C. Hypothermic or normothermic abdominal regional perfusion in high-risk donors with extended warm ischemia times: impact on outcomes? *Transplant international : official journal of the European Society for Organ Transplantation*. 2015;28(6):700-7.
72. Tabet J, García-Valdecasas JC, Rull R, Valero R, Angás J, González FX, et al. Non-heart-beating donor pigs: the feasibility of liver donation. *Transplant Proc*. 1997;29(1-2):1374-5.
73. Valero R, García-Valdecasas JC, Tabet J, Taurá P, Rull R, Beltran J, et al. Hepatic blood flow and oxygen extraction ratio during normothermic recirculation and total body cooling as viability predictors in non-heart-beating donor pigs. *Transplantation*. 1998;66(2):170-6.
74. Koyama I, Hoshino T, Nagashima N, Adachi H, Ueda K, Omoto R. A new approach to kidney procurement from non-heart-beating donors: core cooling on cardiopulmonary bypass. *Transplant Proc*. 1989;21(1 Pt 2):1203-5.
75. Farney AC, Hines MH, al-Geizawi S, Rogers J, Stratta RJ. Lessons learned from a single center's experience with 134 donation after cardiac death donor kidney transplants. *J Am Coll Surg*. 2011;212(4):440-51; discussion 51-3.
76. Koyama I, Taguchi Y, Watanabe T, Nagashima N, Otsuka K, Omoto R. Development of a reliable method for procurement of warm ischemic kidneys from non-heart-beating donors. *Transplant Proc*. 1992;24(4):1327-8.
77. Sánchez-Fructuoso AI, Marques M, Prats D, Conesa J, Calvo N, Pérez-Contín MJ, et al. Victims of cardiac arrest occurring outside the hospital: a source of transplantable kidneys. *Ann Intern Med*. 2006;145(3):157-64.
78. Del Río F, Andrés A, Padilla M, Sánchez-Fructuoso AI, Molina M, Ruiz Á, et al. Kidney transplantation from donors after uncontrolled circulatory death: the Spanish experience. *Kidney Int*. 2019;95(2):420-8.
79. Net M, Valero R, Almenara R, Barros P, Capdevila L, Lopez-Boado MA, et al. The effect of normothermic recirculation is mediated by ischemic preconditioning in NHBD liver transplantation. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2005;5(10):2385-92.
80. Ausania F, White SA, Pocock P, Manas DM. Kidney damage during organ recovery in donation after circulatory death donors: data from UK National Transplant Database. *American journal*

- of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2012;12(4):932-6.
81. Ausania F, White SA, Coates R, Hulme W, Manas DM. Liver damage during organ donor procurement in donation after circulatory death compared with donation after brain death. *Br J Surg.* 2013;100(3):381-6.
 82. Ausania F, Drage M, Manas D, Callaghan CJ. A registry analysis of damage to the deceased donor pancreas during procurement. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.* 2015;15(11):2955-62.

